U.S. Contraceptives Drugs And Devices Market, By Product Type (Contraceptive Drugs, Contraceptive Devices (Male Contraceptive Devices, Female Contraceptive Devices)) - Insights, Opportunity Analysis, and Industry Forecast till 2024

Contraceptive Drugs and Devices – Choice to Conceive, Not Concede

As per stats released by Guttmacher Institute, there were around 61 million women in the U.S. in the childbearing age group (15-44 years) in 2014. Around 10% of these women do not use any contraceptive method. The UN estimates (2015) that unmet need for contraceptives in the North America region is 7%. Thus, there still is an untapped market in the U.S. that contraceptive manufacturers can address. Furthermore, with no-cost coverage insurance policy for sterilization, growth for U.S. contraceptive drugs and devices market is restricted.

Statistics revealed by the United Nations in 2015, mentions that sterilization is a dominant contraceptive method in regions such as North America. Intra-uterine devices (IUDs), vaginal rings, injectables, implants, combined oral contraceptives, and patches are some of the advanced contraceptive methods available in the market. Therefore, various strategies such as promotion through sales force, social media promotion, awareness campaigns, and sampling are adopted by companies marketing contraceptive drugs and devices in the U.S. Introduction of new male contraceptive products with high success rate are projected to shape the course of growth of the U.S. contraceptive drugs and devices market in the near future.

The global U.S. contraceptive drugs and devices market was valued at US$ 6,785.9 million in 2016 and is expected to expand at a CAGR of 5.6% during the forecast period (2016 – 2024)

Figure 1. U.S. Contraceptive Drugs and Devices Market, Major Brand Patent Expirations

Drug/Device Type Brand Patent Expiry Year
Pill Seasonale 2017
Femcon-FE 2019
LO MINASTRIN FE 2019
TAYTULLA 2020
MINASTRIN
24 FE
2019
Yaz 2021
Yasmin 2020
IUD Skyla & Kyleena 2023
Vaginla Ring Nuva-Ring 2018
         Source: Coherent Market Insights Analysis (2016)

Oral pills resulting in volatility in the U.S. contraceptive drugs and devices market

Private companies have high interest in selling contraceptive pills as they generate continuous revenues for them compared to one-time long acting contraceptive methods. Furthermore, patent expiration is projected to lead to a barrage of generics entering into the market, further reducing overall average cost of drugs and in turn market revenue. Global generic pharmaceutical companies such as Teva Pharmaceuticals, Lupin Laboratories and Cipla Limited are at pace to launch their generic versions. Emergency contraceptive pills are among the most popular category of pills owing to extensive promotion activities to market these products.

Favorable reimbursement scenario pushing uptake of contraceptives among low and middle-income population

The U.S. Affordable Care Act emphasizes on complete insurance coverage for long-acting reversible contraceptives (LARC). However, market players are interested in sustainable revenue generating oral pills. This public-private interest disparity impacts cost and product availability in different sections of the society.

Furthermore, the State announced insurance coverage of health and reproductive products to continue without any co-pays, co-insurance or deductibles. In addition to this, the new policy would also cover all medically essential abortion services for the U.S. population. This is a much anticipated relief for the general population in the U.S., where around 45% of all pregnancies reported are unintended (CDC, 2009-2013 study data).

Insurance coverage for devices also varies from state to state in the U.S. Few states have low Medicaid reimbursement rates than the cost of the device, while few states provide reimbursement only to those women who have been prescribed such devices. For instance, in California, dispensing of injectable contraceptives is only allowed by clinics, while Alabama, Idaho, and South California do not cover emergency contraceptive pills as part of the Medicaid programs in their respective states. Many such limitations in Medicaid coverage creates disparity in demand for certain contraceptives across regions in the U.S. Efforts to standardize the rule all over the country is expected to benefit the population at large and the overall U.S. contraceptive drugs and devices market.

Preference for modern contraceptive methods

Higher success rate and availability of reimbursement is encouraging women to opt for these methods over contraceptive pills. With increasing consumer awareness and rising accessibility to modern contraceptives methods, demand for these products is expected to increase during the forecast period. As per the United Nation’s 2015 report, 9 out of 10 married or in-union women opt for modern contraceptive methods. Furthermore, gynecologists and sexologists are recommending use of long-acting reversible contraceptives for couples who do not intend to have a child in near future, owing to their high affectivity compared to conventional contraceptives such as oral hormonal pills.

Contraceptives are birth spacing products that aid in avoiding unplanned pregnancy. There are five widely used contraceptive methods, namely sterilization, hormonal method, barrier method, emergency contraception, and intrauterine method. Sterilization is the most common method implemented globally. While there are a plethora of female contraceptives available in the market, companies and a few University researchers are trying to introduce male contraceptive methods. Women contraceptive methods include vaginal rings, diaphragms, female condoms, oral pills, and intra-uterine devices (IUD). Selecting the most appropriate method is critical to avoid undesired side effects. The use of contraceptives can avoid 60% of maternal deaths and 57% of child deaths worldwide, as opined by the World Health Organization (WHO) in 2014. Therefore, various family planning initiatives have been introduced by governmental and non-governmental agencies in order to create awareness about prevention of unplanned pregnancy.

Market Dynamics

Companies present in the contraceptives market prefer marketing oral contraceptive pills to churn out considerable and constant revenues compared to one-time revenue generated through long-acting contraceptives. Moreover, there is heavy promotion of oral pills compared to the long acting contraceptives such as IUD, and implant. This has kept the consumers away from the real benefits of long acting contraceptives over the oral pills. This is the reason that oral pills dominate the U.S. contraceptive drugs and devices market. The oral pills market is projected to experience the entry of generics with patent expirations nearing in the forecast period.

However, demand for advanced contraceptive options such as IUD, injectables, implants and diaphragms is observed to be high globally. This is owing to growing awareness among the populace, availability of reimbursement and growing demand for long term contraceptive methods. Government promotes the use of IUD and implants i.e. long-acting contraceptives for better therapeutic effect and safety. Also, reimbursement schemes are made attractive for consumers to opt for these contraceptive methods.

Market Taxonomy

This report segments the U.S. contraceptives drugs and devices market on the basis of product type and geography. On the basis of product type, the U.S. contraceptives drugs and devices market is segmented into drug and devices. Drugs are further sub-segmented into oral pills, injectables, and topical contraceptives. The contraceptive devices segment is further sub-segmented into male contraceptives devices and female contraceptives devices. Female contraceptives devices include female condoms, contraceptive diaphragms, contraceptive sponges, and contraceptive vaginal rings. Intrauterine devices, and subdermal contraceptive implants.

Key features of the study:

  • This report provides in-depth analysis of the U.S. contraceptives drugs and devices and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR (%)) for the forecast period: 2016 – 2024, considering 2015 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches, approvals, regional outlook, and competitive strategies adopted by the leading players
  • It profiles leading players in the U.S. contraceptives drugs and devices market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies and future plans
  • Key companies covered as a part of this study include Teva Pharmaceutical Industries Ltd., Church & Dwight Co. Inc., Reckitt Benckiser Plc, Pfizer, Inc., Bayer AG, Mayer Laboratories, Inc., The Female Health Company, Cooper Surgical, Inc., Allergan plc, Cipla Limited, and Merck & Co. Inc.
  • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launches, market expansion, and marketing tactics
  • The U.S. contraceptives drugs and devices market report caters to various stakeholders in this industry, including investors, drug and device manufacturers, distributors and suppliers for contraceptives drugs and devices, government organizations, research and consulting firms, new entrants, and financial analysts
  • Various strategy matrices used in analyzing the contraceptives drugs and devices market would provide stakeholders vital inputs to make strategic decisions accordingly

Detailed Segmentation:

  • U.S. Contraceptives Drugs And Devices Market, By Product Type:
    • Contraceptive Drugs
      • Oral Contraceptive Pills
      • Contraceptive Injectables
      • Topical Contraceptives
    • Contraceptive Devices
      • Male Contraceptive Devices
        • Condoms
      • Female Contraceptive Devices
        • Female Condoms
        • Contraceptive Diaphragms
        • Contraceptive Sponges
        • Contraceptive Vaginal Rings
        • Intrauterine Devices
          • Hormonal
          • Copper-T
        • Subdermal Contraceptive Implants
  • Company Profiles
    • Teva Pharmaceutical Industries Ltd.*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Strategies
      • Recent Developments
      • Future Plans
    • Church & Dwight Co. Inc.
    • Reckitt Benckiser Plc
    • Pfizer, Inc.
    • Bayer AG
    • Mayer Laboratories, Inc.
    • The Female Health Company
    • Cooper Surgical, Inc.
    • Allergan Plc
    • Cipla Limited
    • Merck & Co. Inc.

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objective and assumption
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet By Product Type
      • Market Trends
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Mergers and Acquisitions
    • Technology Overview
    • Promotion Initiatives/Campaigns
    • Reimbursement Scenario
    • Pipeline Analysis
  4. U.S. Contraceptive Drugs and Devices Market, By Product Type, 2014 - 2024 (US$ Million)
    • Introduction
      • Market Share Analysis, 2015 and 2024 (%)
      • Y-O-Y Growth Analysis, 2014 - 2024
      • Segment Trends
    • Drugs
      • Introduction
      • Market Share Analysis, 2015 and 2024 (%)
      • Y-O-Y Growth Analysis, 2014 - 2024
      • Segment Trends
        • Oral Contraceptive Pills
          • Introduction
          • Market Size and Forecast, and Y-O-Y Growth, 2014 - 2024, (US$ Million)
        • Contraceptive Injectables
          • Introduction
          • Market Size and Forecast, and Y-O-Y Growth, 2014 - 2024, (US$ Million)
        • Topical Contraceptives
          • Introduction
          • Market Size and Forecast, and Y-O-Y Growth, 2014 - 2024, (US$ Million)
    • Devices
      • Introduction
      • Market Share Analysis, 2015 and 2024 (%)
      • Y-O-Y Growth Analysis, 2014 - 2024
      • Segment Trends
        • Male Devices
          • Condoms
            • Introduction
            • Market Size and Forecast, and Y-O-Y Growth, 2014 - 2024, (US$ Million)
        • Female Devices
          • Condoms
            • Introduction
            • Market Size and Forecast, and Y-O-Y Growth, 2014 - 2024, (US$ Million)
          • Contraceptive Diaphragms
            • Introduction
            • Market Size and Forecast, and Y-O-Y Growth, 2014 - 2024, (US$ Million)
          • Contraceptive Sponges
            • Introduction
            • Market Size and Forecast, and Y-O-Y Growth, 2014 - 2024, (US$ Million)
          • Contraceptive Vaginal Rings
            • Introduction
            • Market Size and Forecast, and Y-O-Y Growth, 2014 - 2024, (US$ Million)
          • Intrauterine Devices
            • Introduction
            • Market Size and Forecast, and Y-O-Y Growth, 2014 - 2024, (US$ Million)
              1. Hormonal
              2. Copper-T
          • Subdermal Contraceptive Implants
            • Introduction
            • Market Size and Forecast, and Y-O-Y Growth, 2014 - 2024, (US$ Million)
  5. Competitive Landscape
    • Heat Map Analysis
    • Company Profiles
      • Teva Pharmaceutical Industries Ltd.
        • Company Overview
        • Product Type Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Church & Dwight Co. Inc.
        • Company Overview
        • Product Type Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Pfizer, Inc.
        • Company Overview
        • Product Type Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Bayer AG
        • Company Overview
        • Product Type Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Mayer Laboratories, Inc.
        • Company Overview
        • Product Type Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • The Female Health Company
        • Company Overview
        • Product Type Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Merck & Co. Inc.
        • Company Overview
        • Product Type Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Allergan Plc
        • Company Overview
        • Product Type Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Cooper Surgical, Inc.
        • Company Overview
        • Product Type Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Cipla Limited
        • Company Overview
        • Product Type Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • HLL Lifecare
        • Company Overview
        • Product Type Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
    • Analyst Views
  6. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 30 market data tables and 15 figures on "Contraceptive Drugs and Devices Market – U.S. forecast to 2024”.  

Research Methodology

Coherent Market Insights followsa comprehensive research methodology focused on providing the most precise market analysis. The company leverages a data triangulation model which helps company to gauge the market dynamics and provide accurate estimates. Key components of the research methodologies followed for all our market reports include:

  • Primary Research (Trade Surveys and Experts Interviews)
  • Desk Research
  • Proprietor Data Analytics Model

In addition to this, Coherent Market Insights has access to a wide range of the regional and global reputed paid data bases, which helps the company to figure out the regional and global market trends and dynamics. The company analyses the industry from the 360 Degree Perspective i.e. from the Supply Side and Demand Side which enables us to provide granular details of the entire ecosystem for each study. Finally, a Top-Down approach and Bottom-Up approach is followed to arrive at ultimate research findings.


Smiley face

Coherent Market Insights desk research is based on a principle set of research techniques:

  • National level desk research: It Includes research analysis of regional players, regional regulatory bodies, regional trade associations, and regional organization.
  • Multinational level desk research: The research team keeps a track of multinational players, global regulatory bodies, global trade associations, and global organization.

Coherent Market Insights has a large amount of in-house repository of industry database. This is leveraged as a burner for initiating a new research study. Key secondary sources include:

  • Governmental bodies, National and international social welfare institutions, and organizations creating economic policies among others.
  • Trade association, National and international media and trade press.
  • Company Annual reports, SEC filings, Corporate Presentations, press release, news, and specification sheet of manufacturers, system integrators, brick and mortar - distributors and retailers, and third party online commerce players.
  • Scientific journals, and other technical magazines and whitepapers.

Smiley face

Preliminary Data Mining

The raw data is obtained through the secondary findings, in house repositories, and trade surveys. It is then filtered to ensure that the relevant information including industry dynamics, trends, and outlook is retained for further research process.

Data Standardization:

Holistic approach is used to ensure that the granular and uncommon parameters are taken into consideration to ensure accurate results. The information from the paid databases are further combined to the raw data in order to standardize it.

Coherent Statistical model

We arrive at our final research findings through simulation models. Coherent Data Analytics Model is a statistical tool that helps company to forecast market estimates. Few of the parameters considered as a part of the statistical model include:

  • Micro-economic indicators
  • Macro-economic indicators
  • Environmental indicators
  • Socio-political indicators
  • Technology indicators

Data Processing

Once the findings are derived from the statistical model, large volume of data is process to confirm accurate research results. Data analytics and processing tools are adopted to process large chunk of collected informative data. In case, a client customizes the study during the process, the research finding till then are benchmarked, and the process for new research requirement is initiated again.

Data Validation

This is the most crucial stage of the research process. Primary Interviews are conducted to validate the data and analysis. This helps in achieving the following purposes:

  • It provides first-hand information on the market dynamics, outlook, and growth parameters.
  • Industry experts validates the estimates which helps the company to cement the on-going research study.
  • Primary research includes online surveys, face-to face interviews, and telephonic interviews.

The primary research is conducted with the ecosystem players including, but not limited to:

  • Raw Material Suppliers
  • Manufacturers
  • System Integrators
  • Distributors
  • End-users

Choose License Type

"How Can I Help You" ?

Key Benefits

  • Custom Research Solution

    Talk to our research consultant to design an exclusive report as per your research needs.

  • Customer Fulfilment

    We aim to fulfil client's research demands with tailored research solutions.

  • Quick Turnaround Time Reports

    We aim to provide research studies in quickest turnaround time and in a much cost effective manner.

  • 360-degree Approach

    We cover each industry from supply and demand side with an aim to provide a most holistic research study.

  • Assured Quality

    We strive to provide most accurate and reliable research findings in our research reports.